Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Vifor Pharma AG
  6. Summary
    VIFN   CH0364749348

VIFOR PHARMA AG

(VIFN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
06/10/2021 06/11/2021 06/14/2021 06/15/2021 06/16/2021 Date
136.45(c) 137.3(c) 137.55(c) 137(c) 137.9(c) Last
118 274 96 597 88 714 185 783 130 425 Volume
-0.29% +0.62% +0.18% -0.40% +0.66% Change
More quotes
Financials
Sales 2021 1 800 M 1 981 M 1 981 M
Net income 2021 217 M 239 M 239 M
Net cash position 2021 416 M 458 M 458 M
P/E ratio 2021 41,2x
Yield 2021 1,57%
Sales 2022 1 991 M 2 190 M 2 190 M
Net income 2022 285 M 314 M 314 M
Net cash position 2022 683 M 751 M 751 M
P/E ratio 2022 32,6x
Yield 2022 1,73%
Capitalization 8 944 M 9 947 M 9 841 M
EV / Sales 2021 4,74x
EV / Sales 2022 4,15x
Nbr of Employees 2 600
Free-Float 71,7%
More Financials
Company
Vifor Pharma AG, formerly known as Galenica AG, is a Switzerland-based company engaged in the healthcare market. The Company operates through a single pharmaceutical segment. It develops, manufactures and markets pharmaceutical products, specializing in therapies for iron deficiency, nephrology and cardio-renal diseases. The Company's portfolio of iron deficiency treatments includes intravenous products, Ferinject... 
Sector
Pharmaceuticals
Calendar
08/05Earnings Release
More about the company
Ratings of Vifor Pharma AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about VIFOR PHARMA AG
05/10VIFOR PHARMA : Ex-dividend day for final dividend
FA
05/06VIFOR PHARMA  : 93rd Vifor Pharma Group Annual General Meeting
BU
05/06VIFOR PHARMA  : Research Partners Lowers Price Target on Vifor Pharma, Maintains..
MT
04/30VIFOR PHARMA  : VFMCRP announces positive results of phase-III clinical trial of..
BU
04/29VIFOR PHARMA  : Angion Biomedica Complete Enrollment in Mid-Stage Study of Kidne..
MT
04/29VIFOR PHARMA  : and Angion announce completion of enrollment in phase-II study o..
BU
04/28VIFOR PHARMA  : Enrolls First Heart Failure Patient in Global Registry
MT
04/28VIFOR PHARMA  : First patient enrolled in CARE-HK in HF to evaluate role of Velt..
BU
04/19PRESS RELEASE : SYNLAB sets price range for its planned IPO at EUR 18.00 to EUR ..
DJ
03/26VIFOR PHARMA  : to propose Åsa Riisberg for appointment to Board of Directors
BU
03/08VIFOR PHARMA  : Cara Therapeutics Get US FDA Priority Review for Korsuva in Hemo..
MT
03/08VIFOR PHARMA  : Mirabaud Securities Lifts Price Target on Vifor Pharma, Maintain..
MT
03/08VIFOR PHARMA  : Delivers strong full year results 2020
PU
03/08CARA THERAPEUTICS  : New Drug Application for Anti-Itch Injection for Hemodialys..
MT
03/03VIFOR PHARMA  : Full-year results 2020 – Analyst presentation
PU
More news
News in other languages on VIFOR PHARMA AG
05/28EQS-ADHOC : HBM-Portfoliounternehmen Swixx BioPharma kündigt Kapital-erhöhung vo..
05/12Aktien Schweiz: Gegenbewegung bringt SMI knappe Gewinne
05/10Bourse Zurich: dans le rouge pour la première séance de la semaine
05/10Bourse Zurich: toujours en panne à l'approche de la mi-journée
05/10Bourse Zurich: accès de faiblesse à contre-courant des places européennes
More news
Analyst Recommendations on VIFOR PHARMA AG
More recommendations
Chart VIFOR PHARMA AG
Duration : Period :
Vifor Pharma AG Technical Analysis Chart | VIFN | CH0364749348 | MarketScreener
Technical analysis trends VIFOR PHARMA AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 137,71 CHF
Last Close Price 137,90 CHF
Spread / Highest target 41,4%
Spread / Average Target -0,14%
Spread / Lowest Target -14,1%
EPS Revisions
Managers and Directors
NameTitle
Stefan Schulze President, Chief Executive & Operating Officer
Colin Bond Chief Financial Officer
Jacques Theurillat Chairman
Klaus Henning Jensen Chief Medical Officer
Michel Burnier Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VIFOR PHARMA AG-1.44%9 892
JOHNSON & JOHNSON4.48%433 167
ROCHE HOLDING AG11.21%330 710
PFIZER, INC.6.76%221 613
NOVARTIS AG0.77%210 689
ABBVIE INC.7.82%204 582